

ASX Release

Release of Shares from Mandatory Escrow

BRISBANE, 10 July 2018: Oventus Medical Ltd (ASX: OVN) is pleased to announce that in accordance with Listing Rule 3.10A Oventus Medical Ltd (“Oventus”) advises that 37,009,158 fully paid Ordinary Shares and 1,204,392 Options (exercise price of \$0.578 per Option and expire on 23 February 2021) will be released from escrow 10 days from the date of this announcement i.e. 24 July 2018.

The escrow period was initiated upon the successful listing of Oventus on 19 July 2017. The released securities were subject to mandatory escrow arrangements.

Oventus will apply for quotation of the 37,009,158 restricted securities within 10 business days after the end of the escrow period as required by Listing Rule 2.8.2.

Following the quotation of the released shares, there will be 105,939,212 quoted securities. There will be no Shares or Options remaining in escrow.



STEPHEN DENARO / COMPANY SECRETARY

For more information, please contact:

Mr Neil Anderson, Managing Director and CEO: M: 0403 003 475

Jane Lowe, IR Department: M: 0411 117 774 or jane.lowe@irdepartment.com.au

About Oventus

Oventus Medical Ltd (ASX: OVN) is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring.

Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue, reducing airway collapsibility and managing mouth breathing while maintain a stable airway with or without nCPAP. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth.

While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O₂Vent is designed to allow nasal breathing

when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.³

¹ *Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

² *Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003*

³ *Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.*